Torrent Pharmaceuticals Gains Listing and Trading Approval for Equity Shares from NSE and BSE
Torrent Pharmaceuticals Limited has received Final Listing and Trading Approval for a significant tranche of equity shares, marking a key step in its ongoing corporate restructuring following the Scheme of Amalgamation involving J. B. Chemicals & Pharmaceuticals Limited.The company announced that it secured final approval from both the National Stock Exchange of India Limited (NSE) and BSE Limited on July 27, 2026. This approval pertains to 4,19,22,416 fully paid-up Equity shares of Torrent Pharmaceuticals Limited, each valued at ₹ 5/-.
These equity shares were issued and allotted in terms of the Scheme of Amalgamation between J. B. Chemicals & Pharmaceuticals Limited (the Transferor Company) and Torrent Pharmaceuticals Limited.
The allotment of these 4,19,22,416 Equity Shares to eligible shareholders of JB Chemicals was previously intimated on July 20, 2026, based on the Record Date set for Friday, July 17, 2026.
The shares are scheduled to be listed and admitted to dealings on the NSE and BSE starting from July 28, 2026.
Key details of the share allotment and listing approval are as follows:
| Detail | Information |
|---|---|
| Equity Shares Allotted | 4,19,22,416 |
| Issue Price per Share | ₹ 5/- |
| Approval Date (NSE & BSE) | July 27, 2026 |
| Listing Commencement Date | July 28, 2026 |
TORNTPHARM Stock Price Movement
Torrent Pharmaceuticals Limited shares climbed on Monday, settling at ₹5019.5 after gaining 0.98%, translating to a rise of ₹48.50. The stock registered a robust volume of 267,708 shares, achieving a high during the session and closing just short of its 52-week peak.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.